Azasordarins: Susceptibility of Fluconazole-Susceptible and Fluconazole-Resistant Clinical Isolates of
            <i>Candida</i>
            spp. to GW 471558

Cuenca‐Estrella, Manuel; Mellado, Emilia; Diaz-Guerra, Teresa M.; Monzón, Araceli; Rodríguez-Tudela, Juan Luis

doi:10.1128/aac.45.6.1905-1907.2001

Cited by 8 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As metodologias do CLSI e do EUCAST utilizam 0,5% de DMSO como concentração final. Segundo Cuenca-Estrella et al, 34 embora 1% de DMSO pudesse ser utilizado, o controle positivo fluconazol usado neste experimento teve como concentração máxima de DMSO apenas 0,5% no primeiro poço antes de ser diluída. É exatamente o que ambas as metodologias usam como concentração final deste solvente.…”

Section: Resultsunclassified

Estudo comparativo entre as metodologias preconizadas pelo CLSI e pelo EUCAST para avaliação da atividade antifúngica

Stoppa¹,

Casemiro²,

Vinholis³

et al. 2009

Quím. Nova

View full text Add to dashboard Cite

Estudo comparativo EntrE as mEtodologias prEconizadas pElo clsi E pEloRecebido em 2/4/08; aceito em 8/8/08; publicado na web em 5/2/09 COMPARATIVE STUDY OF THE RECOMMENDED METHODOLOGIES BY CLSI AND EUCAST FOR ACTIVITY EVALUATION ANTIFUNGAL. The international organizations CLSI and EUCAST developed reference methodologies for activity evaluation antifungal. The aim of this work was to compare the recommended methodologies by the CLSI and EUCAST in the antifungal activity evaluation of crude extracts of Azadirachta indica and green propolis. The results showed that the MIC values determined by the EUCAST methodology were smaller than that determined by the CLSI. Nevertheless, both methodologies were satisfactory to detect and evaluate antifungal activity of the crude extracts and isolated compounds. The EUCAST methodology showed advantage by making possible to obtain results in less time.

show abstract

Section: Resultsunclassified

Estudo comparativo entre as metodologias preconizadas pelo CLSI e pelo EUCAST para avaliação da atividade antifúngica

Stoppa¹,

Casemiro²,

Vinholis³

et al. 2009

Quím. Nova

View full text Add to dashboard Cite

show abstract

Antifungal Agents

Watkins

Renau

2003

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

The chapter addresses current chemotherapeutic options and trends in the treatment of fungal diseases in humans. The nature of such diseases is discussed, with attendant issues such as relative severity, diagnosis, microbiological methods, and trends in incidence. Emphasis is placed on systemic infections, in which morbidity and mortality are much higher than that in cutaneous diseases. The various drugs with proven clinical utility are then surveyed by chemical class, with a discussion of mode of action, spectrum and emergence of resistance, pharmacokinetic properties, and side effects for each; for the most prominent class of antifungal agents (the azoles), the history of their medicinal evolution is described. Where appropriate, comment is made about new developments in the field with a brief summary of newer agents in clinical development. Also included is a section reviewing chemical series with interesting (and selective) modes of action that have not yet been tested clinically. Finally, the anticipated impact of new technologies on antifungal drug discovery is briefly discussed.

show abstract

Novel Antifungal Therapies

Abu-Elteen

Hamad

2007

New Insights in Medical Mycology

View full text Add to dashboard Cite

Azasordarins: Susceptibility of Fluconazole-Susceptible and Fluconazole-Resistant Clinical Isolates of Candida spp. to GW 471558

Cited by 8 publications

References 6 publications

Estudo comparativo entre as metodologias preconizadas pelo CLSI e pelo EUCAST para avaliação da atividade antifúngica

Estudo comparativo entre as metodologias preconizadas pelo CLSI e pelo EUCAST para avaliação da atividade antifúngica

Antifungal Agents

Novel Antifungal Therapies

Contact Info

Product

Resources

About